Lv12
80 积分 2025-06-24 加入
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1小时前
待确认
Definition and diagnostic criteria of clinical obesity
18天前
已完结
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP‐1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study
20天前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
29天前
已完结
Diabetes in China: epidemiology, pathophysiology and multi-omics
1个月前
已完结
Diagnosis and Treatment of Type 2 Diabetes in Adults
1个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
1个月前
已完结
Tirzepatide: A Review in Type 2 Diabetes
1个月前
已完结
Tirzepatide: A Review in Type 2 Diabetes
1个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study
1个月前
已完结
皖公网安备34019202002308
